Wellington Management Group LLP Purchases Shares of 141,519 Design Therapeutics, Inc. $DSGN

Wellington Management Group LLP purchased a new stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 141,519 shares of the company’s stock, valued at approximately $546,000. Wellington Management Group LLP owned about 0.25% of Design Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the company. American Century Companies Inc. lifted its position in shares of Design Therapeutics by 13.5% during the first quarter. American Century Companies Inc. now owns 44,415 shares of the company’s stock valued at $171,000 after buying an additional 5,300 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Design Therapeutics during the first quarter valued at about $568,000. Palumbo Wealth Management LLC lifted its position in shares of Design Therapeutics by 6.5% during the first quarter. Palumbo Wealth Management LLC now owns 58,278 shares of the company’s stock valued at $225,000 after buying an additional 3,582 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its position in shares of Design Therapeutics by 3.2% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,953,547 shares of the company’s stock valued at $12,053,000 after buying an additional 61,000 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its position in shares of Design Therapeutics by 16.0% during the fourth quarter. Point72 Asset Management L.P. now owns 1,856,750 shares of the company’s stock valued at $11,456,000 after buying an additional 256,010 shares during the last quarter. 56.64% of the stock is owned by hedge funds and other institutional investors.

Design Therapeutics Stock Performance

DSGN stock opened at $5.53 on Tuesday. The firm has a market cap of $314.93 million, a price-to-earnings ratio of -4.94 and a beta of 1.61. The firm has a 50-day simple moving average of $4.36 and a two-hundred day simple moving average of $4.15. Design Therapeutics, Inc. has a one year low of $2.60 and a one year high of $7.77.

Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.02). As a group, equities analysts predict that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.